Potential utility of statins, 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors in diabetic retinopathy

Yamagishi, 2005, Diabetic vascular complications: pathophysiology, biochemical basis and potential therapeutic strategy, Curr Pharm Des, 11, 2279, 10.2174/1381612054367300 The Diabetes Control and Complications Trial Research Group, 1993, The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus, N Engl J Med, 329, 977, 10.1056/NEJM199309303291401 UK Prospective Diabetes Study (UKPDS) Group, 1998, Intensive blood glucose control with sulphonylureas or insulin compared with conventional treatment and risk complications in patients with type 2 diabetes (UKPDS33), Lancet, 352, 837, 10.1016/S0140-6736(98)07019-6 Wegewitz, 2005, Novel approaches in the treatment of angiogenic eye disease, Curr Pharm Des, 11, 2311, 10.2174/1381612054367292 Yamagishi, 2003, Role of advanced glycation end products (AGEs) and their receptor (RAGE) in the pathogenesis of diabetic microangiopathy, Int J Clin Pharmacol Res, 23, 129 Takeuchi, 2004, TAGE (toxic AGEs) hypothesis in various chronic diseases, Med Hypothese, 63, 449, 10.1016/j.mehy.2004.02.042 Takeuchi, 2004, Alternative routes for the formation of glyceraldehydes-derived AGEs (TAGE) in vivo, Med Hypothese, 63, 453, 10.1016/j.mehy.2004.03.005 Vlassara, 1994, Pathogenic effects of advanced glycosylation: biochemical, biologic, and clinical implications for diabetes and aging, Lab Invest, 70, 138 Bierhaus, 1998, AGEs and their interaction with AGE-receptors in vascular disease and diabetes mellitus. I. The AGE concept, Cardiovasc Res, 37, 586, 10.1016/S0008-6363(97)00233-2 Yamagishi, 2005, Advanced glycation end products (AGEs) and diabetic vascular complications, Curr Diabetes Rev, 1, 93, 10.2174/1573399052952631 Schmidt, 2000, Atherosclerosis and diabetes: the RAGE connection, Curr Atheroscler Rep, 2, 430, 10.1007/s11883-000-0082-4 Takeuchi, 2004, Advanced glycation end products (AGEs) inhibitors and their therapeutic implications in diseases, Int J Clin Pharm Res, 24, 95 Yamagishi, 2005, Therapeutic implications of blockers of advanced glycation end products (AGEs)-their receptor (RAGE) system, Int J Pharm, 1, 203, 10.3923/ijp.2005.203.209 Yamagishi, 2004, Nifedipine inhibits gene expression of receptor for advanced glycation end products (RAGE) in endothelial cells by suppressing reactive oxygen species generation, Drugs Exp Clin Res, 30, 169 Abe, 2004, Regulation of human melanoma growth and metastasis by AGE–AGE receptor interactions, J Invest Dermatol, 122, 461, 10.1046/j.0022-202X.2004.22218.x Collins, 2003, MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5,963 people with diabetes: a randomized placebo-controlled trial, Lancet, 361, 2005, 10.1016/S0140-6736(03)13636-7 Colhoun, 2004, Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomized placebo-controlled trial, Lancet, 364, 685, 10.1016/S0140-6736(04)16895-5 Baghdasarian, 2004, Association of dyslipidemia and effects of statins on nonmacrovascular diseases, Clin Ther, 26, 337, 10.1016/S0149-2918(04)90031-8 Gupta, 2004, Lipid-lowering drug atorvastatin as an adjunct in the management of diabetic macular edema, Am J Ophthalmol, 137, 675 Sen, 2002, Simvastatin retards progression of diabetic retinopathy in diabetic patients with hypercholesterolemia, Diabetes Res Clin Pract, 56, 1, 10.1016/S0168-8227(01)00341-2 Okamoto, 2002, Angiogenesis induced by advanced glycation end products and its prevention by cerivastatin, FASEB J, 16, 1928, 10.1096/fj.02-0030fje Wirkinson-Berka, 2004, Vasoactive factors and diabetic retinopathy: vascular endothelial growth factor, cyclooxygenase-2 and nitric oxide, Curr Pharm Des, 10, 3331, 10.2174/1381612043383142 Onorato, 2000, Pyridoxamine, an inhibitor of advanced glycation reactions, also inhibits advanced lipoxidation reactions. Mechanism of action of pyridoxamine, J Biol Chem, 275, 21177, 10.1074/jbc.M003263200